CTOs on the Move

Phathom Pharmaceuticals

www.phathompharma.com

 
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Phathom Pharmaceuticals raised $50M on 05/15/2019
Phathom Pharmaceuticals raised $90M on 05/15/2019

Similar Companies

UrgentPoint

Reimagining Healthcare. UrgentPoint is committed to combining health and wellness and meeting the patient where they are, every time. With a multispecialty medical group, a medical management company, and an electronic health records technology company...

New York Cancer and Blood Specialists

New York Cancer & Blood Specialists is committed to our patients. We are dedicated to providing each patient with a unique path to treatment and unmatched support. We strive to make quality, comprehensive cancer care available to each and every patient throughout New York.

ARYx Therapeutics

ARYx Therapeutics, Inc. is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HealthiVibe

HealthiVibe captures patient insights around clinical trial design and patient-centered initiatives. We believe the patient voice is critical in healthcare.

Solara Active Pharma Sciences

Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer-oriented API manufacturer. We have a legacy of over three decades and trace our origins to the API expertise of Strides Shasun Ltd. and the technical knowhow of human API business from Sequent Scientific Ltd. We are poised to bridge the industry gap by delivering value-based products while maintaining focus on customer needs. We have 140+ scientists working at our two R&D Centers and 4 API manufacturing facilities armed with global approvals and 2 dedicated R&D facilities.